 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || BG-1805 / Hedy Group
Enrollment open, Trial initiation date: Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 29, 2024
P1/2, N=24, Recruiting, Sponsor: Guangzhou Bio-gene Technology Co., Ltd
Not yet recruiting --> Recruiting | Initiation date: Nov 2023 --> Mar 2024
- || BG-1805 / Hedy Group
New P1/2 trial: Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 7, 2023
P1/2, N=24, Not yet recruiting, Sponsor: Guangzhou Bio-gene Technology Co., Ltd
- azacitidine / Generic mfg.
[VIRTUAL] The efficacy and safety of anti-CLL1 based CAR-T cells in children with relapsed or refractory acute myeloid leukemia: A multicenter interim analysis. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1268;
For patients showing MRD+ with CLL1 negative AML blast, chemotherapy like Azacitidine, and combined with HSCT may help those patients to reach complete response . These initial results suggested that anti-CLL1 base CAR-T cells can be a well-tolerated and candidate option for treating children with R/R-AML.